Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.49 |
| ▸ | TTR | P02766 | 3/20 | 0.42 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30792072 | 0.87 | TPMT (0.55) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL30792131 | 0.84 | VCAM1 (0.52) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL11799631 | 0.84 | GPR35 (0.61) | GPR35TTRABCC3ABCC4NR1I2 | |
| SCHEMBL47718 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL1730836 | 0.80 | ALDH1A1 (0.55) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL6036460 | 0.80 | TTR (0.62) | MEN1KMT2AGPR35TTRABCC3 | |
| Dinoterb SCHEMBL11379609 | 0.79 | KMT2A (0.70) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL12326836 | 0.79 | MAPT (0.51) | MEN1KMT2AL3MBTL1LMNAMAPT | |
| SCHEMBL4297256 | 0.78 | GPR35 (0.61) | SMN1; SMN2KMT2AGPR35TTRABCC3 | |
| SCHEMBL17500084 | 0.78 | GPR35 (0.69) | SMN1; SMN2MEN1GALR3HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385039-B1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | EISAI R&D MAN CO LTD (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2385039-B1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | EISAI R&D MAN CO LTD (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-1614680-B1 | Process for preparing 2-iminopyrrolidine derivatives | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| EP-1614680-B1 | Process for preparing 2-iminopyrrolidine derivatives | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011140936-A1 | 5,5-DISUBSTITUTED-2-IMINO-PYRROLIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | 上海恒瑞医药有限公司 (CN) | 2011-11-17 | — | — | WO | disclosed |
| EP-2385039-A1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | Eisai R&D Management Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | SMN1; SMN2 2355/4885MEN1 891/4885GALR3 1261/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | SMN1; SMN2 2369/4885MEN1 859/4885GALR3 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.